Wells Trecaso Financial Group LLC Acquires 175 Shares of Johnson & Johnson $JNJ

Wells Trecaso Financial Group LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.3% in the second quarter, Holdings Channel reports. The institutional investor owned 52,886 shares of the company’s stock after acquiring an additional 175 shares during the quarter. Johnson & Johnson accounts for approximately 2.5% of Wells Trecaso Financial Group LLC’s investment portfolio, making the stock its 13th biggest holding. Wells Trecaso Financial Group LLC’s holdings in Johnson & Johnson were worth $8,078,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. Highline Wealth Partners LLC grew its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the first quarter valued at $52,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Bank of America lifted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday. HSBC raised their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $188.88.

Johnson & Johnson Trading Up 1.4%

NYSE:JNJ opened at $188.51 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The stock has a market cap of $453.98 billion, a price-to-earnings ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a 50-day moving average price of $176.18 and a 200-day moving average price of $162.83. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.